AUSTIN, Texas - s4story -- Direct Biologics, LLC will serve as an Educational Sponsor of an upcoming educational webinar produced by ARDS Alliance, Inc. focused on Acute Respiratory Distress Syndrome, Extracellular Vesicle science, secretome research and investigational biologic approaches.

Supported through an educational grant from Direct Biologics, the webinar is being independently developed and produced by ARDS Alliance. The program is intended to provide patients, caregivers and other members of the ARDS community with accurate, science-based educational information and to help address common misconceptions surrounding investigational approaches, including their regulatory status.

The educational program will feature an independent physician or researcher as well as a patient perspective highlighting the experience and impact of ARDS. ARDS Alliance will independently select the speakers and maintain sole editorial control over the webinar and its educational content.

More on S For Story

• Michael H. Kaplan Recognized for 17 Years on PHPA Workers' Compensation Panel and Advocacy for Professional Athletes
• International Society of Medical AI Convenes Global Faculty in Florence for ISMAI 2026
• Boston Industrial Solutions Introduces Personalized Printing Training
• Century Fasteners de Mexico Exhibiting at the 2026 Automotive & Aerospace Nearshoring Summit
• Eagle Book Publishing Expands Publishing Support for UK Authors

"The importance of independent, science-based education for patients and families, and our appreciation for the educational support that makes these programs possible, cannot be overstated," said Paula Blonski, President of ARDS Alliance.

"ARDS is a complex and serious condition, and access to credible, understandable scientific information is important for patients and families navigating it," said Tim Moseley PhD, CSO of Direct Biologics. "We are pleased to support ARDS Alliance in its efforts to provide independent education to the ARDS community."

Direct Biologics' sponsorship is limited to financial support of the educational program and does not provide the company with editorial control over the webinar. Sponsorship does not constitute an endorsement by ARDS Alliance of Direct Biologics, its products or any specific therapy.

The webinar is expected to take place later this year with the recording available through ARDS Alliance and Direct Biologics.

The ARDS Alliance is dedicated to improving ARDS outcomes. By collaborating with patient advocates, healthcare experts, and scientific researchers, the ARDS Alliance works to accelerate research, improve clinical recognition, and advance the global standard of care for respiratory failure.

More on S For Story

• Retell AI White Label Platform for Agencies Launched by VoiceAIWrapper, With Branded Client Portals and No Per-Minute Markup
• New Book Announcement - Nixon's War with Students: Campus Unrest in the Vietnam Era
• New Book Announcement - Shokhí: A Kanza Relative, a Monument, and Rematriation
• FOCUS Names Mark Phillips Senior Vice President of Business Development
• Notaron Expands Online Notarization Access Following Wisconsin Approval

Direct Biologics (https://www.directbiologics.com/) develops investigational secretome-based products under cGMP standards, guided by scientific rigor. All candidate therapies are investigational and have not been approved by the U.S. Food and Drug Administration.

Important Notice
The ARDS Alliance webinar is an independent educational program produced and controlled solely by ARDS Alliance. Direct Biologics' sponsorship does not constitute endorsement by ARDS Alliance of Direct Biologics, its products or any specific therapy. Any investigational therapies discussed during the educational program are under investigation and have not been approved by the U.S. Food and Drug Administration for the indications discussed, unless expressly identified otherwise. The webinar is intended solely for educational purposes and is not intended to provide medical advice, establish a standard of care or recommend the use of any investigational or approved product.